WCC 2014:CHADS2评分可预测房颤导管消融患者并发症?

2014-05-07 高晓方 译 医学论坛网

首都医科大学附属北京安贞医院马长生、董建增等探讨了CHADS2评分系统是否可以预测接受导管消融治疗房颤患者的并发症,结果表明,CHADS2评分能够有效预测上述患者的并发症。 此项回顾性研究共纳入251例接受导管消融的房颤患者。就计算CHADS2而言,以卒中或短暂性脑缺血发作病史计2分,以年龄≥65岁、高血压病史、糖尿病、近期心衰分别计1分。评估CHADS2评分能否在导管消融房颤患者中预测并发症。



首都医科大学附属北京安贞医院马长生、董建增等探讨了CHADS2评分系统是否可以预测接受导管消融治疗房颤患者的并发症,结果表明,CHADS2评分能够有效预测上述患者的并发症。

此项回顾性研究共纳入251例接受导管消融的房颤患者。就计算CHADS2而言,以卒中或短暂性脑缺血发作病史计2分,以年龄≥65岁、高血压病史、糖尿病、近期心衰分别计1分。评估CHADS2评分能否在导管消融房颤患者中预测并发症。

结果显示,CHADS2评分为0、1和≥2的患者分别为109、75和67例。三组患者在房颤持续时间、房颤类型、左房直径、左室舒张末期直径、左室收缩末期直径和射血分数方面均无差异。共出现27例(10.7%)并发症。三组患者的并发症发生率分别为8.3%、8.0%和17.9%。在出现并发症的患者中CHADS2评分显著升高。血栓和出血并发症随CHADS2评分升高而显著增多。与无糖尿病和卒中病史的患者相比,伴上述病史患者的并发症发生率显著升高((32.1 VS. 8.1%,P<0.001))。

文章译自本届世界心脏病学大会(WCC2014)的口头报告摘要,摘要号为0096。

口头报告摘要标题:Can CHADS2 score predict complications in catheter ablation of atrial fibrillation?

作者:Ri-Bo Tang*, Chang-Sheng Ma, Jian-Zeng Dong, De-Yong Long, Rong-Hui Yu

Beijing An Zhen Hospital, Beijing, China


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2029487, encodeId=a871202948e9c, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Wed Feb 18 09:25:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757607, encodeId=4c891e57607c4, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Nov 27 19:25:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661848, encodeId=a5e71661848af, content=<a href='/topic/show?id=6db418632f5' target=_blank style='color:#2F92EE;'>#WCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18632, encryptionId=6db418632f5, topicName=WCC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99ed25348784, createdName=ms3153534357578991, createdTime=Thu Aug 07 12:25:00 CST 2014, time=2014-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399587, encodeId=8d21139958ed8, content=<a href='/topic/show?id=9a0546e31b5' target=_blank style='color:#2F92EE;'>#导管消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46731, encryptionId=9a0546e31b5, topicName=导管消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd042221840, createdName=wjcjjian, createdTime=Fri May 09 04:25:00 CST 2014, time=2014-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421592, encodeId=4cad142159270, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Fri May 09 04:25:00 CST 2014, time=2014-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9316, encodeId=4fa89316ee, content=CHA2DS2-VASc新的评分系统会不会更有效?值得研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed May 07 20:28:00 CST 2014, time=2014-05-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2029487, encodeId=a871202948e9c, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Wed Feb 18 09:25:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757607, encodeId=4c891e57607c4, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Nov 27 19:25:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661848, encodeId=a5e71661848af, content=<a href='/topic/show?id=6db418632f5' target=_blank style='color:#2F92EE;'>#WCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18632, encryptionId=6db418632f5, topicName=WCC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99ed25348784, createdName=ms3153534357578991, createdTime=Thu Aug 07 12:25:00 CST 2014, time=2014-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399587, encodeId=8d21139958ed8, content=<a href='/topic/show?id=9a0546e31b5' target=_blank style='color:#2F92EE;'>#导管消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46731, encryptionId=9a0546e31b5, topicName=导管消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd042221840, createdName=wjcjjian, createdTime=Fri May 09 04:25:00 CST 2014, time=2014-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421592, encodeId=4cad142159270, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Fri May 09 04:25:00 CST 2014, time=2014-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9316, encodeId=4fa89316ee, content=CHA2DS2-VASc新的评分系统会不会更有效?值得研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed May 07 20:28:00 CST 2014, time=2014-05-07, status=1, ipAttribution=)]
    2014-11-27 丁鹏鹏
  3. [GetPortalCommentsPageByObjectIdResponse(id=2029487, encodeId=a871202948e9c, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Wed Feb 18 09:25:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757607, encodeId=4c891e57607c4, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Nov 27 19:25:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661848, encodeId=a5e71661848af, content=<a href='/topic/show?id=6db418632f5' target=_blank style='color:#2F92EE;'>#WCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18632, encryptionId=6db418632f5, topicName=WCC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99ed25348784, createdName=ms3153534357578991, createdTime=Thu Aug 07 12:25:00 CST 2014, time=2014-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399587, encodeId=8d21139958ed8, content=<a href='/topic/show?id=9a0546e31b5' target=_blank style='color:#2F92EE;'>#导管消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46731, encryptionId=9a0546e31b5, topicName=导管消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd042221840, createdName=wjcjjian, createdTime=Fri May 09 04:25:00 CST 2014, time=2014-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421592, encodeId=4cad142159270, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Fri May 09 04:25:00 CST 2014, time=2014-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9316, encodeId=4fa89316ee, content=CHA2DS2-VASc新的评分系统会不会更有效?值得研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed May 07 20:28:00 CST 2014, time=2014-05-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2029487, encodeId=a871202948e9c, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Wed Feb 18 09:25:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757607, encodeId=4c891e57607c4, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Nov 27 19:25:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661848, encodeId=a5e71661848af, content=<a href='/topic/show?id=6db418632f5' target=_blank style='color:#2F92EE;'>#WCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18632, encryptionId=6db418632f5, topicName=WCC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99ed25348784, createdName=ms3153534357578991, createdTime=Thu Aug 07 12:25:00 CST 2014, time=2014-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399587, encodeId=8d21139958ed8, content=<a href='/topic/show?id=9a0546e31b5' target=_blank style='color:#2F92EE;'>#导管消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46731, encryptionId=9a0546e31b5, topicName=导管消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd042221840, createdName=wjcjjian, createdTime=Fri May 09 04:25:00 CST 2014, time=2014-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421592, encodeId=4cad142159270, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Fri May 09 04:25:00 CST 2014, time=2014-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9316, encodeId=4fa89316ee, content=CHA2DS2-VASc新的评分系统会不会更有效?值得研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed May 07 20:28:00 CST 2014, time=2014-05-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2029487, encodeId=a871202948e9c, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Wed Feb 18 09:25:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757607, encodeId=4c891e57607c4, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Nov 27 19:25:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661848, encodeId=a5e71661848af, content=<a href='/topic/show?id=6db418632f5' target=_blank style='color:#2F92EE;'>#WCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18632, encryptionId=6db418632f5, topicName=WCC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99ed25348784, createdName=ms3153534357578991, createdTime=Thu Aug 07 12:25:00 CST 2014, time=2014-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399587, encodeId=8d21139958ed8, content=<a href='/topic/show?id=9a0546e31b5' target=_blank style='color:#2F92EE;'>#导管消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46731, encryptionId=9a0546e31b5, topicName=导管消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd042221840, createdName=wjcjjian, createdTime=Fri May 09 04:25:00 CST 2014, time=2014-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421592, encodeId=4cad142159270, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Fri May 09 04:25:00 CST 2014, time=2014-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9316, encodeId=4fa89316ee, content=CHA2DS2-VASc新的评分系统会不会更有效?值得研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed May 07 20:28:00 CST 2014, time=2014-05-07, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2029487, encodeId=a871202948e9c, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Wed Feb 18 09:25:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757607, encodeId=4c891e57607c4, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Nov 27 19:25:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661848, encodeId=a5e71661848af, content=<a href='/topic/show?id=6db418632f5' target=_blank style='color:#2F92EE;'>#WCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18632, encryptionId=6db418632f5, topicName=WCC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99ed25348784, createdName=ms3153534357578991, createdTime=Thu Aug 07 12:25:00 CST 2014, time=2014-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399587, encodeId=8d21139958ed8, content=<a href='/topic/show?id=9a0546e31b5' target=_blank style='color:#2F92EE;'>#导管消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46731, encryptionId=9a0546e31b5, topicName=导管消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd042221840, createdName=wjcjjian, createdTime=Fri May 09 04:25:00 CST 2014, time=2014-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421592, encodeId=4cad142159270, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Fri May 09 04:25:00 CST 2014, time=2014-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9316, encodeId=4fa89316ee, content=CHA2DS2-VASc新的评分系统会不会更有效?值得研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed May 07 20:28:00 CST 2014, time=2014-05-07, status=1, ipAttribution=)]
    2014-05-07 lovetcm

    CHA2DS2-VASc新的评分系统会不会更有效?值得研究

    0

相关资讯

伊伐布雷定或可治疗血管迷走性晕厥

  2012年世界心脏病学大会于4月18~21日在阿联酋迪拜召开,会上报告了摩纳哥学者开展的一项小样本研究。研究人员发现伊伐布雷定对心源性疼痛的治疗有确切作用,并认为伊伐布雷定对其他适合限制最高心率的疾病可能也有用;上述在虚脱之前伴明显心动过速的血管迷走性晕厥(VVS)病人中开展的研究,或许表明了伊伐布雷定有另一个适应证的可能性。   伊伐布雷定是一种抑制窦房结舒张期去极化的药物,据报告它

WCC 2014:射血分数减少的慢性心衰患者临床特征和长期预后

中国医学科学院阜外心血管病医院的学者们探讨了中国射血分数减少型慢性心衰(CHF—REF)患者的当前治疗状态,评估了此类患者的长期生存情况,分析其全因死亡和心脏性猝死(SCD)的独立预测因素。结果表明,尽管中国CHF—REF患者(尤其是扩张型心肌病患者)经过了当前的标准治疗,但其预后仍然较差。应辨别CHF—REF患者全因死亡和SCD的预测因素,以更好的评估这些患者的预后。 该研究纳入10所医院的2

WCC 2014:2014年世界心脏病大会预告

2014年世界心脏病大会(WCC2014)将于2014年5月4日-7日在澳大利亚的墨尔本召开,主办方为世界心脏病联盟。联盟先有200多个会员组织,致力于在全球范围内(尤其是中低收入国家)抗击心脏病和卒中。世界心脏病联盟与其会员组织努力促成全球各国承诺在政策层面来解决心血管健康问题,生成和交流思想,共享最佳规范,推动科学研究,促进知识传播,从而共同征服心血管疾病这一全球头号杀手。世界心脏病联盟的会员

急性心梗PCI后多血管病变的治疗策略

  2012年世界心脏病学大会于近日报告了荷兰学者对多血管病变ST段抬高型心肌梗死(STEMI)的直接经皮冠脉介入(PCI)治疗就诊患者开展的一项研究。研究人员发现:在当前日常临床实践的4种急性心梗和多支血管病变病人的治疗策略中,计划血运重建组【预期2期经皮冠脉介入(PCI)和计划冠脉旁路移植术(CABG)】在长期随访期间的生存率高于1期PCI或药物治疗组;当前数据支持2期PCI是多支血管病变ST

非手术中心无保护左主干病变PCI安全有效

  2012年世界心脏病学大会于4月18~21日在阿联酋迪拜召开,会上公布的英国学者的一项研究表明:在高容量非手术中心,所有年龄组病人的无保护左主干冠脉(ULMCA)经皮冠脉介入(PCI)治疗成功率高,死亡率低;尽管1/4的病人采用了2个支架策略,进行了积极的冠脉血管造影(IVUS)随访,但靶血管血运重建(TVR)仍很低。在上述病人队列中,ULMCA PCI不但安全而且有效。PCI是高龄

巴西长达7年全国性队列研究:PTCA对比CABG

  2012年世界心脏病学大会于4月18~21日在阿联酋迪拜召开,会上公布了巴西学者在冠脉血运重建病人中开展的一项比较经皮冠状动脉腔内成形术(PTCA)和冠状动脉旁路移植术(CABG)对冠状动脉疾病病人的临床益处的全国性队列研究。该研究果显示:年龄和CABG而非性别与预后独立相关。   目前经皮冠状动脉腔内成形术(PTCA)相较于CABG对冠状动脉疾病病人的临床益处。这项研究旨在评估PTCA或C